Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive entities : Atyr pharma, inc. save search
aTyr Pharma Presents New Data on Efzofitimod Mechanism of Action and Positive Exposure-Response at the American Thoracic Society 2023 International Conference
Published: 2023-05-22 (Crawled : 12:00) - globenewswire.com
LIFE | $1.595 -1.54% -1.57% 290K
|
Health Technology
|
| O: 2.05%
H: 0.8%
C: -2.01%
pharma conference positive international efzofitimod
aTyr Pharma Announces Publication of Positive Data from Phase 1b/2a Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal CHEST
Published: 2022-11-09 (Crawled : 15:00) - biospace.com/
LIFE | $1.595 -1.54% -1.57% 290K
|
Health Technology
|
| O: 0.0%
H: 0.21%
C: -4.62%
treatment pharma positive publication study phase 2b
aTyr Pharma Announces Positive End-of-Phase 2 Meeting with FDA on Efzofitimod for the Treatment of Pulmonary Sarcoidosis
Published: 2022-03-10 (Crawled : 14:00) - globenewswire.com
LIFE | $1.595 -1.54% -1.57% 290K
|
Health Technology
|
| O: 3.62%
H: 6.6%
C: 2.33%
treatment fda phase 2 pos positive
aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Announce Positive Data from a Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response of ATYR1923 in Pulmonary Sarcoidosis
Published: 2021-09-13 (Crawled : 12:00) - globenewswire.com
LIFE | $1.595 -1.54% -1.57% 290K
|
Health Technology
|
| O: 14.96%
H: 47.46%
C: 45.24%
biopharma phase 1 positive trial phase 1b phase 2b
aTyr Pharma Announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response for ATYR1923 in Pulmonary Sarcoidosis
Published: 2021-09-13 (Crawled : 12:00) - globenewswire.com
LIFE | $1.595 -1.54% -1.57% 290K
|
Health Technology
|
| O: 14.96%
H: 47.46%
C: 45.24%
phase 1 positive trial phase 1b phase 2b response
aTyr Pharma Announces Positive Biomarker Data from Phase 2 Clinical Trial of ATYR1923 Demonstrating Anti-Inflammatory Effects in COVID-19 Patients with Severe Respiratory Complications
Published: 2021-03-15 (Crawled : 15:00) - biospace.com/
LIFE | $1.595 -1.54% -1.57% 290K
|
Health Technology
|
| O: 4.41%
H: 1.42%
C: -5.39%
covid phase 2 positive respiratory trial biomarkers
aTyr Pharma Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications
Published: 2021-01-04 (Crawled : 22:00) - globenewswire.com
LIFE | $1.595 -1.54% -1.57% 290K
|
Health Technology
|
| O: 0.5%
H: 4.01%
C: -3.51%
covid positive results respiratory trial topline phase 2
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.